Vanda Pharmaceuticals Announces Presentations at SLEEP 2024

WASHINGTON, May 29, 2024 — Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced participation at SLEEP 2024, to be held in Houston, TX from June 1 through June 5, 2024.

The following will be presented:

June 4, 2024

Presentation Title: "Drug Screening and CRISPR/Cas9 Screening of HCN Channels" Poster Presentation Session: P-17 Poster Number: 10 Presenter: Dr. Sandra Paulina Smieszek, Head of Genetics

Presentation Title: "Melanopsin Crispants in Zebrafish Display Difference in Sleep Latency" Poster Presentation Session: P-17 Poster Number: 11 Presenter: Dr. Sandra Paulina Smieszek, Head of Genetics

Presentation Title: "Genetic Variants Associated with Dim Light Melatonin Onset in a Delayed Sleep-Wake Phase Disorder Cohort" Poster Presentation Session: P-22 Poster Number: 146 Presenter: Dr. Sandra Paulina Smieszek, Head of Genetics

Presentation Title: "Genetic variants associated with TST and LPS in insomnia patients: whole genome sequencing study" Poster Presentation Session: Late-Breaking Abstracts (LBA); P-31 Poster Number: 451 Presenter: Dr. Sandra Paulina Smieszek, Head of Genetics

For more information on SLEEP 2024, please refer to https://www.sleepmeeting.org/

About Vanda Pharmaceuticals Inc.

Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com and follow us on X @vandapharma.

Corporate Contact: Kevin Moran Senior Vice President, Chief Financial Officer and Treasurer Vanda Pharmaceuticals Inc. 202-734-3400 [email protected]

Jim Golden / Jack Kelleher / Dan Moore Collected Strategies [email protected]